The U.S. Food and Drug Administration has approved a generic drug application from Apotex, marking a potential new entrant into the market and driving intense pressure on competitor pricing. This regulatory milestone challenges the current revenue streams of branded market leaders, likely triggering strategies to protect margins in an increasingly competitive landscape.